H3G34-Mutant Gliomas-A Review of Molecular Pathogenesis and Therapeutic Options

Area of Science:

• Neuro-oncology
• Molecular Biology
• Genetics

Background:

• The 2021 WHO CNS tumor classification introduced H3.3-G34R/V mutant gliomas (pediatric-type diffuse hemispheric glioma) alongside H3-K27M altered gliomas (diffuse midline glioma).
• Both H3.3-G34R/V and H3-K27M gliomas are associated with poor prognoses, particularly in pediatric populations.
• H3.3-G34R/V mutant gliomas remain significantly understudied compared to H3-K27M altered gliomas.

Purpose of the Study:

• To consolidate current knowledge on H3.3-G34R/V mutant gliomas.
• To elucidate the molecular mechanisms driving gliomagenesis in this specific subtype.
• To review diagnostic criteria, treatment options, long-term outcomes, and potential future therapies.

Main Methods:

• Comprehensive literature review of studies on H3.3-G34R/V mutant gliomas.
• Analysis of molecular mechanisms, including oncohistone roles in gliomagenesis.
• Synthesis of data on clinical diagnosis, therapeutic interventions, and patient outcomes.

Main Results:

• H3.3-G34R/V mutations are key drivers of pediatric-type diffuse hemispheric gliomas.
• Understanding gliomagenesis is crucial for developing targeted therapies.
• Current treatment strategies offer limited long-term survival benefits.

Conclusions:

• H3.3-G34R/V mutant gliomas require further research attention due to their poor prognosis and understudied nature.
• Advances in understanding molecular mechanisms may lead to novel therapeutic targets.
• Future research should focus on improving diagnosis and treatment efficacy for these rare pediatric brain tumors.